



ASX release

16 March 2010

AtCor Medical launches new Platform for clinicians

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness non-invasively, this week launched its latest SphygmoCor software (Version 9) at the Annual American College of Cardiology Scientific Session Exposition being held in Atlanta on March 14-16, 2010.

The new SphygmoCor offers improvements to simplify clinical use, and will assist evaluation of cardiovascular status and management of patient care by medical specialists, particularly cardiologists, hypertension specialists, nephrologists and endocrinologists.

New features include a real-time 'auto capture' system which makes it easier for clinicians to capture cardiovascular data, and improved 'clinically-friendly' graphic reporting. This innovation represents the first stage of an ongoing program of development to broaden use of SphygmoCor in the specialist clinical market. Measurement of central blood pressure using SphygmoCor is made through a noninvasive ten-second measurement taken at the patient's wrist, and test results are available instantly.

"Our goal is to continually make SphygmoCor systems more easy and convenient for clinicians," said Duncan R. Ross, AtCor Medical President and CEO. "We have a continuing dialogue with our customers and our applications engineers who train new customers, to uncover opportunities to improve our products and support services."

Auto Capture

The new Auto Capture system assesses the quality of the radial pressure wave forms that are being monitored in real time, assists the operator with screen prompts on technique, and automatically captures test results once acceptable data has been recorded.

The new Platform also offers redesigned clinical reports, which support efficient and accurate tests interpretation with succinct, graphically simplified data displays. Clinical reports visually highlight test results that may indicate increased patient risk, such as elevated central pulse pressure.

SphygmoCor systems— evolving to meet new clinical and research needs

Duncan Ross said, "In 2008, we introduced a new, lightweight and portable system design, with a smaller footprint than the average laptop computer. It allows noninvasive central pressure testing to be conveniently performed in any clinical setting. In 2009 we introduced a new system enhancement for the clinical trials market, the AtCor WISDOM system, which allows us to offer our pharma clinical trials customers real-time data assessment and operator coaching in remote investigator sites. In 2010, we are introducing SphygmoCor Version 9, the latest product of AtCor's ongoing technology development program. We have many more innovations in development."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 799 8221

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au